Payment overview · 2025
General Payments
$37,983.75
205 reported records · 20 companies
Healthcare provider profile · identity verified
Huachen Wei, MD
Allopathic & Osteopathic Physicians|Dermatology · ELMHURST, NY · NPI 1235167313
Verified facts
What the public records show
CMS Open Payments records show Huachen Wei, MD received $37,983.75 in general payments during 2025 across 205 reported records.
Janssen Biotech, Inc. accounted for 48.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Opzelura, Otezla, Rinvoq, Skyrizi, Tremfya, Vtama, Zoryve.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SKYRIZI as an associated drug or biological on 322790 records involving 36751 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Skyrizi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Otezla by this doctor in 2024.
Arcutis Biotherapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zoryve as an associated drug or biological on 56906 records involving 10745 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Zoryve by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPZELURA as an associated drug or biological on 59568 records involving 12571 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Opzelura by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STELARA as an associated drug or biological on 23706 records involving 7279 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Stelara by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Tremfya by this doctor in 2024.
Organon LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VTAMA as an associated drug or biological on 29859 records involving 10220 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Vtama by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $18,565.40 | 48.9% | 45 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17,208.30 | 45.3% | 35 | 2025 |
| Arcutis Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $300.11 | 0.8% | 24 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $234.81 | 0.6% | 13 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $218.55 | 0.6% | 12 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $203.76 | 0.5% | 10 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $198.32 | 0.5% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $184.08 | 0.5% | 8 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $183.18 | 0.5% | 12 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $121.31 | 0.3% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $114.74 | 0.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $98.94 | 0.3% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $91.31 | 0.2% | 4 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $82.70 | 0.2% | 4 | 2025 |
| Helsinn Therapeutics (U.S.), Inc. | Unresolved — no canonical attribution shown | $60.85 | 0.2% | 3 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $37.64 | 0.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $22.05 | 0.1% | 1 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $21.00 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.81 | 0.1% | 1 | 2025 |
| LNHC, Inc | Unresolved — no canonical attribution shown | $17.89 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,812.50 | 12 |
| Food and Beverage | $4,292.00 | 190 |
| Travel and Lodging | $780.25 | 2 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $18,565.40 | 45 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $17,031.84 | 24 | 2025 |
Source payment records
|
|||||
| Zoryve Normalized: zoryve |
Drug | Arcutis Biotherapeutics, Inc. | $300.11 | 24 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI US SERVICES INC. | $227.05 | 11 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $218.55 | 12 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $198.68 | 11 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $183.18 | 12 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $176.88 | 8 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $176.46 | 11 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $160.11 | 7 | 2025 |
Source payment records
|
|||||
| LITFULO Normalized: litfulo |
Drug | PFIZER INC. | $157.55 | 6 | 2025 |
Source payment records
|
|||||
| ANZUPGO Normalized: anzupgo |
Drug | LEO Pharma Inc. | $124.76 | 8 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $121.31 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $98.94 | 4 | 2025 |
Source payment records
|
|||||
| ILUMYA Normalized: ilumya |
Biological | SUN PHARMACEUTICAL INDUSTRIES INC. | $82.70 | 4 | 2025 |
Source payment records
|
|||||
| ADBRY Normalized: adbry |
Biological | LEO Pharma Inc. | $73.56 | 6 | 2025 |
Source payment records
|
|||||
| VALCHLOR Normalized: valchlor |
Drug | Helsinn Therapeutics (U.S.), Inc. | $60.85 | 3 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $37.64 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $37.64 | 1 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| ZELSUVMI Normalized: zelsuvmi |
Drug | LNHC, Inc | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $15.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OPZELURA opzelura |
2025 | Opzelura | 2024 | 34 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 77 | exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SKYRIZI skyrizi |
2025 | Skyrizi | 2024 | 48 | exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 139 | exact normalized | Medicare Part D |
| VTAMA vtama |
2025 | Vtama | 2024 | 110 | exact normalized | Medicare Part D |
| Zoryve zoryve |
2025 | Zoryve | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SKYRIZI open payments reported associated product |
CMS Open Payments — General Payments 322790 supporting records · 36751 recipient NPIs · example record 1201352600 |
Skyrizi · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
| Arcutis Biotherapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Zoryve open payments reported associated product |
CMS Open Payments — General Payments 56906 supporting records · 10745 recipient NPIs · example record 1252324094 |
Zoryve · 2024 Exact normalized brand match · 1 Part D row |
84 | 44 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | OPZELURA open payments reported associated product |
CMS Open Payments — General Payments 59568 supporting records · 12571 recipient NPIs · example record 1225959946 |
Opzelura · 2024 Exact normalized brand match · 1 Part D row |
34 | 16 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | STELARA open payments reported associated product |
CMS Open Payments — General Payments 23706 supporting records · 7279 recipient NPIs · example record 1174257377 |
Stelara · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
139 | 32 |
| Organon LLC Exact reporting entity; no affiliate inference |
2025 | VTAMA open payments reported associated product |
CMS Open Payments — General Payments 29859 supporting records · 10220 recipient NPIs · example record 1237634330 |
Vtama · 2024 Exact normalized brand match · 1 Part D row |
110 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ketoconazole | Ketoconazole | 1907 | 654 |
| Mupirocin | Mupirocin | 1733 | 1394 |
| Ammonium Lactate | Ammonium Lactate | 1701 | 811 |
| Clobetasol Propionate | Clobetasol Propionate | 1342 | 668 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 1138 | 774 |
| Mometasone Furoate | Mometasone Furoate | 1112 | 817 |
| Halobetasol Propionate | Halobetasol Propionate | 1042 | 764 |
| Ciclopirox | Ciclopirox Olamine | 842 | 476 |
| Fluocinonide | Fluocinonide | 781 | 480 |
| Hydrocortisone | Hydrocortisone | 668 | 506 |
| Dupixent Syringe | Dupilumab | 386 | 69 |
| Prednisone | Prednisone | 374 | 285 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 370 | 304 |
| Tacrolimus | Tacrolimus | 363 | 168 |
| Metronidazole | Metronidazole | 321 | 148 |
| Ciclopirox | Ciclopirox | 320 | 161 |
| Dupixent Pen | Dupilumab | 232 | 49 |
| Terbinafine Hcl | Terbinafine Hcl | 198 | 161 |
| Clindamycin Phosphate | Clindamycin Phosphate | 178 | 103 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 174 | 86 |
| Clotrimazole | Clotrimazole | 170 | 76 |
| Valacyclovir | Valacyclovir Hcl | 142 | 118 |
| Tremfya | Guselkumab | 139 | 32 |
| Meloxicam | Meloxicam | 122 | 65 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 115 | 74 |
| Calcipotriene | Calcipotriene | 110 | 34 |
| Vtama | Tapinarof | 110 | 34 |
| Cephalexin | Cephalexin | 105 | 101 |
| Skyrizi Pen | Risankizumab-Rzaa | 85 | 28 |
| Zoryve | Roflumilast | 84 | 44 |
| Minocycline Hcl | Minocycline Hcl | 83 | 42 |
| Nystatin | Nystatin | 81 | 47 |
| Otezla | Apremilast | 77 | 14 |
| Erythromycin | Erythromycin Base In Ethanol | 66 | 43 |
| Fluconazole | Fluconazole | 61 | 46 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 36 |
| Silver Sulfadiazine | Silver Sulfadiazine | 57 | 45 |
| Imiquimod | Imiquimod | 54 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 38 |
| Acyclovir | Acyclovir | 51 | 32 |
| Rinvoq | Upadacitinib | 50 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 49 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 49 | 29 |
| Skyrizi | Risankizumab-Rzaa | 48 | 16 |
| Taltz Autoinjector | Ixekizumab | 45 | suppressed |
| Gabapentin | Gabapentin | 39 | 23 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 38 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 24 |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 35 | suppressed |
| Opzelura | Ruxolitinib Phosphate | 34 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 24 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | 18 |
| Stelara | Ustekinumab | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Desonide | Desonide | 22 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 22 | suppressed |
| Sotyktu | Deucravacitinib | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | 14 |
| Humira(Cf) Pen | Adalimumab | 21 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 20 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Nystop | Nystatin | 17 | 12 |
| Acitretin | Acitretin | 15 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 15 | 11 |
| Permethrin | Permethrin | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | 13 |
| Cosentyx Unoready Pen | Secukinumab | 13 | suppressed |
| Amcinonide | Amcinonide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37,983.75 · 205 records | Janssen Biotech, Inc. | ADBRY, ANZUPGO, Bimzelx, CIBINQO, COLLAGENASE SANTYL, COSENTYX, DUPIXENT, EBGLYSS, ILUMYA, LITFULO, NEMLUVIO, NEXPLANON, Natroba, OPZELURA, OTEZLA, RINVOQ, Rhapsido, SKYRIZI, Spinosad, TREMFYA, VALCHLOR, VTAMA, ZELSUVMI, Zoryve | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Opzelura play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error